OBJECTIVES: Previous works have reported that the transplantation of neural stem cells (NSCs) may improve functional recovery after spinal cord injury (SCI), but these results have been mainly obtained in rat models. In the present work, the authors sought to determine whether the transplantation of human NSCs improves functional outcome in a canine SCI model and whether transplanted NSCs survive and differentiate. METHODS: Human NSCs (HB1. F3 clone) were used in this work. Lateral hemisection at the L2 level was performed in dogs and either (1) Matrigel (200 microl) alone as a growth-promoting matrix or (2) Matrigel seeded with human NSCs (10(7) cells/200 microl) were transplanted into hemisected gaps. Using a canine hind limb locomotor scale, functional outcomes were assessed over 12 weeks. Immunofluorescence staining was performed to examine cell survival, differentiation and axonal regeneration. RESULTS: Compared with dogs treated with Matrigel alone, dogs treated with Matrigel + human NSCs showed significantly better functional recovery (10.3 +/- 0.7 versus 15.6 +/- 0.7, respectively, at 12 weeks; p<0.05). Human nuclei-positive cells were found mainly near hemisected areas in dogs treated with Matrigel + NSCs. In addition, colocalization of human nuclei and neuronal nuclei or myelin basic protein was clearly observed. Moreover, the Matrigel + NSC group showed more ascending sensory axon regeneration. CONCLUSIONS: The transplantation of human NSCs has beneficial effects on functional recovery after SCI, and these NSCs were found to differentiate into mature neurons and/or oligodendrocytes. These results provide baseline data for future clinical applications.
OBJECTIVES: Previous works have reported that the transplantation of neural stem cells (NSCs) may improve functional recovery after spinal cord injury (SCI), but these results have been mainly obtained in rat models. In the present work, the authors sought to determine whether the transplantation of human NSCs improves functional outcome in a canine SCI model and whether transplanted NSCs survive and differentiate. METHODS:Human NSCs (HB1. F3 clone) were used in this work. Lateral hemisection at the L2 level was performed in dogs and either (1) Matrigel (200 microl) alone as a growth-promoting matrix or (2) Matrigel seeded with human NSCs (10(7) cells/200 microl) were transplanted into hemisected gaps. Using a canine hind limb locomotor scale, functional outcomes were assessed over 12 weeks. Immunofluorescence staining was performed to examine cell survival, differentiation and axonal regeneration. RESULTS: Compared with dogs treated with Matrigel alone, dogs treated with Matrigel + human NSCs showed significantly better functional recovery (10.3 +/- 0.7 versus 15.6 +/- 0.7, respectively, at 12 weeks; p<0.05). Human nuclei-positive cells were found mainly near hemisected areas in dogs treated with Matrigel + NSCs. In addition, colocalization of human nuclei and neuronal nuclei or myelin basic protein was clearly observed. Moreover, the Matrigel + NSC group showed more ascending sensory axon regeneration. CONCLUSIONS: The transplantation of human NSCs has beneficial effects on functional recovery after SCI, and these NSCs were found to differentiate into mature neurons and/or oligodendrocytes. These results provide baseline data for future clinical applications.
Authors: Barbara Gericota; Joseph S Anderson; Gaela Mitchell; Dori L Borjesson; Beverly K Sturges; Jan A Nolta; Maya Sieber-Blum Journal: Stem Cells Transl Med Date: 2014-01-17 Impact factor: 6.940
Authors: Veronica Martínez-Cerdeño; Bonnie L Barrilleaux; Ashley McDonough; Jeanelle Ariza; Benjamin T K Yuen; Priyanka Somanath; Catherine T Le; Craig Steward; Kayla Horton-Sparks; Paul S Knoepfler Journal: Stem Cells Dev Date: 2017-08-22 Impact factor: 3.272
Authors: Wolfram Tetzlaff; Elena B Okon; Soheila Karimi-Abdolrezaee; Caitlin E Hill; Joseph S Sparling; Jason R Plemel; Ward T Plunet; Eve C Tsai; Darryl Baptiste; Laura J Smithson; Michael D Kawaja; Michael G Fehlings; Brian K Kwon Journal: J Neurotrauma Date: 2010-04-20 Impact factor: 5.269
Authors: Jared T Wilcox; Jonathan K Y Lai; Esther Semple; Brigitte A Brisson; Cathy Gartley; John N Armstrong; Dean H Betts Journal: PLoS One Date: 2011-05-17 Impact factor: 3.240
Authors: Barbara G McMahill; Dori L Borjesson; Maya Sieber-Blum; Jan A Nolta; Beverly K Sturges Journal: Stem Cell Rev Rep Date: 2015-02 Impact factor: 5.739
Authors: Takashi Amemori; Nataliya Romanyuk; Pavla Jendelova; Vit Herynek; Karolina Turnovcova; Pavel Prochazka; Miroslava Kapcalova; Graham Cocks; Jack Price; Eva Sykova Journal: Stem Cell Res Ther Date: 2013-06-07 Impact factor: 6.832